NASDAQ:SLN Silence Therapeutics (SLN) Stock Price, News & Analysis $19.83 +0.03 (+0.15%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$19.84 +0.01 (+0.03%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Silence Therapeutics Stock (NASDAQ:SLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Silence Therapeutics alerts:Sign Up Key Stats Today's Range$19.76▼$19.8650-Day Range$8.68▼$19.8352-Week Range$4.19▼$19.86Volume586,512 shsAverage Volume5.72 million shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingHold Company Overview Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders. Silence Therapeutics focuses on developing medicines rather than selling marketed products, and it has worked with pharmaceutical partners to advance RNAi programs. Founded in 1994, the company has roots in Germany and is headquartered in London. Its activities include research, drug development and collaborations with partners in markets beyond the United Kingdom.AI Generated. May Contain Errors. Read More Silence Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreSLN MarketRank™: 2.829842931935 of 5 starsSilence Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 448th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingSilence Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialSilence Therapeutics has a consensus price target of $24.00, representing about 21.0% upside from its current price of $19.83.Amount of Analyst CoverageSilence Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Silence Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Silence Therapeutics are expected to decrease in the coming year, from ($0.82) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -18.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -18.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 15.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.01% of the float of Silence Therapeutics has been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently decreased by 17.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.25 News SentimentSilence Therapeutics has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Silence Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Silence Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.00% of the stock of Silence Therapeutics is held by insiders.Percentage Held by Institutions98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Silence Therapeutics' insider trading history. Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLN Stock News HeadlinesSilence Therapeutics plc: Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial ResultsNovember 12 at 9:14 AM | finanznachrichten.deSilence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLNOctober 21, 2026 | businesswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)October 20, 2026 | globenewswire.comSilence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%October 19, 2026 | insidermonkey.comSilence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares SurgeOctober 19, 2026 | finance.yahoo.comSilence Therapeutics Soars 125% on All-Cash $1.3 Billion Merck KGaA Buyout: “Immediate and Certain”October 19, 2026 | finance.yahoo.comSilence Therapeutics Stock Soars 126% On Merck KGaA Acquisition DealOctober 19, 2026 | rttnews.comSee More Headlines SLN Stock Analysis - Frequently Asked Questions How have SLN shares performed this year? Silence Therapeutics' stock was trading at $6.08 on January 1st, 2026. Since then, SLN shares have increased by 226.2% and is now trading at $19.83. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.13. Silence Therapeutics had a negative trailing twelve-month return on equity of 102.72% and a negative net margin of 8,943.86%. Who are Silence Therapeutics' major shareholders? Top institutional investors of Silence Therapeutics include Nantahala Capital Management LLC (1.87%), Aberdeen Group plc (0.34%), Marshall Wace LLP (0.10%) and State Street Corp (0.04%). How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Super Micro Computer (SMCI), Micron Technology (MU), Nkarta (NKTX), argenex (ARGX) and Atai Beckley (ATAI). Company Calendar Last Earnings11/12/2026Today11/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, SLN's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SLN CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees88Year Founded1999Price Target and Rating Average Price Target for Silence Therapeutics$24.00 High Price Target$32.00 Low Price Target$20.00 Potential Upside/Downside+21.0%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.61 million Net Margins-8,943.86% Pretax Margin-9,748.13% Return on Equity-102.72% Return on Assets-43.70% Debt Debt-to-Equity RatioN/A Current Ratio7.42 Quick Ratio7.42 Sales & Book Value Annual Sales$560 thousand Price / Sales2,200.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book15.02Miscellaneous Outstanding Shares62,150,000Free Float60,289,000Market Cap$1.23 billion OptionableOptionable Beta1.34 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:SLN) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredSHOCKING! Prediction caught on cameraNewly released footage shows James Altucher pulling a document out of a briefcase on camera. It is a document ...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
